semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Gestational Diabetes Mellitus Neonatal Hyperbilirubinemia Neonatal Asphyxia People in the study should meet the following Must be a singleton pregnancy Clinical diagnosis of gestational diabetes mellitus according to ACOG Practice Bulletin  Pregnant women and neonates were excluded if they met the (not included in if meeting one of following items ) Maternal clinical diseases (hypertension disorders, abnormal liver function, Rhesus negative blood group or other blood system disease) Maternal other pregnancy complications (polyhydramnios, oligohydramnios, placenta praevia, and abruptio placentae) Delivery before 37 weeks or after 42 weeks Neonatal weight was < 2.5 kg or>4.0 kg Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease and so on, whether prenatal suspicion or diagnosis postpartum) Neonatal septicemia, hemolytic disease or other diseases affecting bilirubin metabolism
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.493,  Biliary Atresia preliminary work up for cholestasis suspected or inconclusive diagnosis of BA. 2. Serum Direct bilirubin > 2 mg/dl,GGT> 100 U/L 3. Male or female infants with a gestational age> 36 weeks 4. Admission weight > 2 kg 5. Age > 14 days days at diagnosis 6. For Kasai operated subjects, Type 3 or 4 anatomy of BA 7. For Kasai operated subjects, cholangiogram (if performed) diagnostic of BA 8. Liver biopsy supporting BA diagnosis  Patients having access to liver transplantation for immediate liver failure 2. Prior Kasai patients 3. Major cardiac, renal, central nervous system (CNS) malformations 4. Intracranial hemorrhage 5. History of recent total parenteral nutrition (TPN) use within the last 2 weeks 6. Gl tract obstruction For Kasai-operated subjects: Type 1 or 2 biliary atresia anatomy 7. Current systemic infection 8. WBC > 20,000 cells/uL 9. Platelet count < 20,000 cells/uL or >1 million cells/uL 10. Concurrent respiratory, metabolic, neurological, cardiovascular, metabolic, and renal illness 11. Elevated serum creatinine > 1 mg/dL 12. Purpura fulminans or unexplained vascular thrombosis
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Pre-Eclampsia Singleton pregnancy Gestational age up to 34 weeks and above  Multiple pregnancy Gestational age less than 34 weeks
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Elastography Fibrosis, Liver Pediatrics Chronic Liver Disease Patients younger than 18 years of age with chronic liver disease who underwent a transient elastography Parents / legal guardians and the patients themselves, if applicable, have read, understood and signed the informed consent of the study  Patients who do not meet all the for in the study protocol
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cholangitis, Secondary Biliary Cholangiocarcinoma Obstructive Jaundice Pancreas Cancer COVID-19 SARS-CoV-2 Patients referred for ERCP or EUS during the study period  Patients refusing to participate in the study
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.077,  Neonatal Jaundice we included appropriate for gestational age full-term infants with pathological unconjugated hyperbilirubinemia who are candidate for phototherapy according to American academy of pediatrics guidelines  Full term infants with intrauterine growth restriction, congenital malformations, conjugated hyperbilirubinemia, severe jaundice initially required exchange transfusion, skin abrasions or infection, and preterm infants were excluded
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.077,  Neonatal Jaundice Appropriate for gestational age full-term infants with pathological unconjugated hyperbilirubinaemia who are candidate for photo therapy according to American academy guidelines  Preterm infants, newborn infant with congenital malformations, conjugated hyperbilirubinamia, small for gestational age, in need of exchange transfusion, and skin abrasions or infections
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Hyperbilirubinemia, Neonatal Jaundice, Neonatal • Normal delivery of the mother Mother being primiparous Newborn being >38 GW Having no multiple infants Absence of congenital anomaly (craniofacial abnormality such as cleft palate, cleft lip, paralysis of facial muscles) in the newborn No blood incompatibility between mother and father Exclusive breastfeeding of the newborn Non-contraindication of the mother's milk to her infant Absence of the mother's diagnosed psychiatric story Mother's openness to communication and cooperation  • Separation of the mother and the infant due to any situation
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.558,  Bronchopulmonary Dysplasia of Newborn Documented informed consent from parent or guardian, prior to study procedures 2. < 29 weeks gestational age at birth 3. 32-40 weeks postmenstrual age 4. Receiving respiratory support at enrollment If 32-36 weeks postmenstrual age: mechanical ventilation (high frequency or conventional) If > 36-40 weeks postmenstrual age: mechanical ventilation (high frequency or conventional) OR continuous positive airway pressure (CPAP) Note: 3 and 4 define severe BPD for the purposes of this study CPAP is defined as any of the following Nasal cannula > 2 liters per minute (LPM) Nasal continuous positive airway pressure (NCPAP) Nasal intermittent positive pressure ventilation (NIPPV) Noninvasive neurally adjusted ventilatory assist (NAVA) Any other device designed to provide positive pressure through a nasal device (e.g., RAM cannula, etc.)  Previous enrollment and dosing in this study, protocol number (NHLBI-2019-SIL), "Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (BPD)" 2. Previous exposure to sildenafil within 7 days prior to randomization* 3. Previous exposure to vasopressors within 24 hours prior to randomization* 4. Previous exposure to inhaled nitric oxide within 24 hours prior to randomization 5. Evidence of pulmonary hypertension or moderate/large patent ductus arteriosus (PDA) on the most recent echocardiogram performed within 14 days prior to randomization 6. Known major congenital heart defect requiring medical or surgical intervention in the neonatal period 7. Known allergy to sildenafil 8. Known sickle cell disease 9. Aspartate aminotransferase (AST) > 225 U/L < 72 hours prior to randomization 10. Alanine aminotransferase (ALT) > 150 U/L < 72 hours prior to randomization 11. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study Participant will be reassessed prior to dosing to reconfirm criteria
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.442-0.615,  Infant, Premature, Diseases Birth weight between 750 g-1500 g ≤ 32 weeks gestational age at birth. GA will be determined by an ultrasound scan or the neonatologist's estimate, with consideration to maternal date Subject has been classified as appropriate for GA (AGA) Enteral feeding of human milk must be initiated by 21 days of life for infants with a birthweight of 750-1000 g (birth date is day of life 0) and initiated by 14 days of life for infants with a birthweight of 1.0 5 kg birthweight Mother agrees to feed the infant human milk as the exclusive feeding during the study period. Human milk may be mothers own or donor milk, plus Singleton or twin births only  Serious congenital abnormalities or underlying disease that may affect growth and development minute APGAR: 5 4 Steroids used within the past 5 days Grade Ill or IV periventricular/ intraventricular hemorrhage (PVH/IVH) Maternal cocaine, alcohol or opioid abuse during pregnancy or currently or if the mother or infant is currently receiving treatment for HIV infection Infant major surgery (intra-thoracic or intra-abdominal procedures or other surgery requiring general anesthesia) Asphyxia defined as progressive hypoxemia and hypercapnia with significant metabolic acidemia characterized by APGAR score <3 at 10 minutes, seizures within the first 12 hours of life, or a cord blood gas < 7.0 and seizures and/or severe tonic abnormalities in the first 12 hours of life Infant has any other condition that, in the opinion of the investigator, compromises the ability to draw inference about the ability of the to support growth
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pharmacokinetics adults (> 18 years) Non smokers Biological parameters within normal range (blood count, urea, creatinine, AST, ALT, GGT, bilirubine) BMI within 18 and 25 Negative urinary and plasma pregnancy test Informed consent  participation to another study with incompatible procedure regarding the French law on research Treatment with a drug drug interaction with tacrolimus Cardiac rhythm at rest below 50 bpm Cardiac issue detected on electrocardiogram Cancer or history of cancer Chronic infection or history of chronic infection Diabetes or history of diabetes Hypertension or history of hypertension Pregnancy or lactation Deprived of liberty (curatorship, guardianship or incarcerate)
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.5,  Anemia of Prematurity Very Low Birth Weight Infant <1500 g at birth, expected to live beyond 2 weeks, not yet started on oral iron supplementation (OIS), with mother at least 18 years of age, and parental consent  congenital intestinal defects, history of intestinal infection or perforation before OIS. Infants who require epogen for religious reason to prevent them from getting blood transfusions will be excluded from the study
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.417,  Infant, Premature, Diseases Continuous Positive Airway Pressure Positive-Pressure Respiration Resuscitation Respiratory Distress Syndrome, Newborn Born before 32 weeks gestational age by best obstetric estimate  Infants with major congenital anomalies
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.115,  Jaundice, Neonatal All the following conditions must be met 1. Term newborns admitted to hospital with "neonatal hyperbilirubinemia" 2. Exclusive breastfeeding or mainly breastfeeding 3. perinatal infection, G-6P-D deficiency, homoimmune hemolysis, polycythemia, scalp hematoma, intracranial hemorrhage, cholestasis, hypoglycemia, hypothyroidism, hypothermia, neonatal asphyxia, fetus Pathological jaundice factors such as delayed stool excretion  As long as any one of the following conditions should be excluded 1. During the follow-up period, breastfeeding was terminated or the daily milk powder intake exceeded 200 ml. 2. Other pathological jaundice was diagnosed during the follow-up period. 3. Take probiotics during the sampling period. 4. The guardian asked to withdraw from the study halfway